Lexeo Total Assets from 2010 to 2026
| LXEO Stock | 7.04 0.12 1.68% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 169 M | Current Value 121 M | Quarterly Volatility 53.8 M |
Check Lexeo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexeo Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9 M or Depreciation And Amortization of 2.4 M, as well as many indicators such as Price To Sales Ratio of 377, Dividend Yield of 0.0 or PTB Ratio of 1.69. Lexeo financial statements analysis is a perfect complement when working with Lexeo Therapeutics Valuation or Volatility modules.
Lexeo | Total Assets | Build AI portfolio with Lexeo Stock |
Evaluating Lexeo Therapeutics's Total Assets across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Lexeo Therapeutics Common's fundamental strength.
Latest Lexeo Therapeutics' Total Assets Growth Pattern
Below is the plot of the Total Assets of Lexeo Therapeutics Common over the last few years. Total assets refers to the total amount of Lexeo Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lexeo Therapeutics Common books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Lexeo Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexeo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 146.94 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Lexeo Total Assets Regression Statistics
| Arithmetic Mean | 66,717,125 | |
| Geometric Mean | 50,119,371 | |
| Coefficient Of Variation | 80.66 | |
| Mean Deviation | 48,280,740 | |
| Median | 29,409,281 | |
| Standard Deviation | 53,815,498 | |
| Sample Variance | 2896.1T | |
| Range | 139.6M | |
| R-Value | 0.82 | |
| Mean Square Error | 1018.2T | |
| R-Squared | 0.67 | |
| Significance | 0.000058 | |
| Slope | 8,725,769 | |
| Total Sum of Squares | 46337.7T |
Lexeo Total Assets History
Other Fundumenentals of Lexeo Therapeutics Common
Lexeo Therapeutics Total Assets component correlations
Click cells to compare fundamentals
About Lexeo Therapeutics Financial Statements
Lexeo Therapeutics investors utilize fundamental indicators, such as Total Assets, to predict how Lexeo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 169 M | 121 M |
Pair Trading with Lexeo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Lexeo Stock
The ability to find closely correlated positions to Lexeo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics Common to buy it.
The correlation of Lexeo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexeo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Lexeo Therapeutics Correlation against competitors. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Biotechnology sector continue expanding? Could Lexeo diversify its offerings? Factors like these will boost the valuation of Lexeo Therapeutics. Expected growth trajectory for Lexeo significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lexeo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Lexeo Therapeutics Common using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Lexeo Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Lexeo Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Lexeo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lexeo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Lexeo Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.